Yes. A PSEN1 genetic test can change dementia care decisions as symptoms progress, because a confirmed result opens specific treatment trials, clarifies the expected disease course, and triggers decisions for the whole family.
PSEN1 is a gene that, when mutated, causes early-onset Alzheimer's disease to pass directly from parent to child. PSEN1 mutations are the most common known genetic cause of this inherited form of the disease, accounting for an estimated 18 to 50 percent of familial early-onset cases with a clear inheritance pattern, according to a PreventionGenetics test description citing an American Journal of Medical Genetics review. For a family already watching symptoms worsen, a positive result is not just a label — it changes which treatments are available and what to tell at-risk relatives.
Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.
Table of Contents
- What a PSEN1 Result Actually Confirms
- Who Qualifies for Testing, and When
- How a Confirmed Result Opens Specific Treatment Trials
- Decisions Beyond Medication
- Practical Steps for a Family Facing Progressing Symptoms
- Frequently Asked Questions
What a PSEN1 Result Actually Confirms
A PSEN1 test looks for a specific mutation in the presenilin-1 gene, one of three genes tied to autosomal-dominant Alzheimer's — the other two are APP and PSEN2. Combined diagnostic testing of all three genes identifies a causative variant in roughly 40 to 80 percent of families who meet clinical criteria for early-onset familial Alzheimer's disease, based on lab yield data summarized in a Highmark medical policy on Alzheimer's genetic testing. PSEN1 carriers tend to develop symptoms earlier and progress faster than carriers of the other two genes, with a mean age of onset around 43.
Penetrance is high, meaning almost everyone who inherits the mutation eventually develops the disease, but the exact symptoms, severity, and pace still differ between carriers, even within the same family, according to PreventionGenetics' test information. That variability matters once symptoms are already progressing. A confirmed PSEN1 mutation tells a care team what is driving the decline and roughly what trajectory to expect, but it does not predict the day-to-day course for that specific person. Families should treat the result as a framework for planning, not a fixed timeline.
Who Qualifies for Testing, and When
Clinical policy criteria allow diagnostic PSEN1 testing for people who already have symptoms of early-onset dementia, defined as onset at or before age 65. For relatives who are asymptomatic or only minimally symptomatic, testing is limited to the single variant already identified in an affected family member, and genetic counseling is required both before and after the test, per Blue Shield of California's medical policy on Alzheimer's genetic testing. This two-tier structure matters for families managing an active case. The person with worsening symptoms can pursue full diagnostic testing to confirm the cause.
Their children or siblings, who may show no symptoms yet, can only be tested for that one known family variant — not a broad panel — and only after counseling that covers what a positive or negative result will mean for them. A separate safeguard applies when a relative, rather than the patient, is the one pushing for testing. Genetic counselors are expected to screen for conflicts of interest in that situation and should not proceed against the patient's own wishes. DNA banking is offered as a middle path: a blood sample is preserved for future testing without disclosing any result now, according to guidance summarized by Guideline Central.
How a Confirmed Result Opens Specific Treatment Trials
The clearest way a PSEN1 result changes care as symptoms progress is treatment access. A confirmed Alzheimer's-causing mutation such as PSEN1 is the enrollment criterion for the Dominantly Inherited Alzheimer Network trial, DIAN-TU-001, which has enrolled 197 participants and gives symptomatic carriers open-label lecanemab alongside a randomized assignment to the investigational drug E2814 or placebo, according to its ClinicalTrials.gov record. A related study, DIAN-TU-003, extends access further: carriers who already completed an earlier gantenerumab extension can continue into this open-label study, which provides lecanemab to confirmed dominantly-inherited-Alzheimer's-disease mutation carriers for a minimum of five years, per a research summary from the UK Health Research Authority.
Neither pathway is reachable without a documented mutation on file. This is distinct from how lecanemab is approved for sporadic Alzheimer's disease — the more common form with no single inherited cause. There, Europe's Committee for Medicinal Products for Human Use narrowed its approval recommendation to patients with zero or one copy of the APOE4 gene variant, after subgroup data showed that patients with two copies face substantially higher risk of ARIA, a type of brain swelling or bleeding linked to amyloid-clearing drugs, according to European Medicines Agency news. APOE4 status, not PSEN1, drives that particular eligibility decision — a reminder that different genes answer different questions about the same drug class.
Decisions Beyond Medication
A confirmed or excluded PSEN1 result informs decisions that extend well past which drug a person can take. These include life and employment planning, informing at-risk relatives of their own odds, and reproductive decisions for younger family members who have not yet had children, according to the University of Washington Memory and Brain Wellness Center. As symptoms progress in the person who carries the mutation, these downstream effects become urgent rather than theoretical.
A sibling who learns they also carry the variant may choose to finalize legal and financial plans earlier, pursue trial enrollment while still asymptomatic, or coordinate caregiving responsibilities with other relatives. A negative result in a relative closes off that line of worry for that individual, even while the original diagnosis in their family member still needs care. Because the mutation is autosomal dominant — each child of a carrier has a 50 percent chance of inheriting it — a single confirmed test result in one symptomatic family member effectively reframes risk for everyone in that bloodline, not just the person tested.
Practical Steps for a Family Facing Progressing Symptoms
Families navigating a worsening diagnosis can take a few concrete steps once a PSEN1 mutation is suspected or confirmed: A documented PSEN1 result, once in hand, becomes the single piece of paperwork that trial coordinators, counselors, and specialists all ask for first — making it worth obtaining even when the immediate medical picture feels settled.
- Confirm symptom onset age and family history with a clinician before requesting diagnostic testing, since criteria generally require onset at or before 65.
- Pursue genetic counseling before and after any test, for both the symptomatic patient and any relative being considered for single-variant testing.
- Ask the care team whether a confirmed result qualifies the patient for DIAN-TU-001 or DIAN-TU-003, since both require a documented dominant mutation.
- If a relative is asymptomatic but anxious for an answer, consider DNA banking as a way to preserve a sample without forcing a disclosure decision now.
- Treat a positive result as a planning tool for legal, financial, and family decisions, not only a medical diagnosis.
Frequently Asked Questions
Does a PSEN1 test tell you exactly when symptoms will get worse?
No. Penetrance is high, meaning carriers nearly always develop the disease, but the exact symptoms, severity, and pace still vary between individual carriers, even within the same family.
Can a worried relative force a family member to get tested?
No. Counselors are expected to screen for conflicts of interest when a relative pushes for testing and should not proceed against the patient's own wishes; DNA banking preserves a sample without disclosing a result.
Is PSEN1 testing the same as APOE4 testing?
No. PSEN1 identifies a dominant inherited mutation and drives eligibility for trials like DIAN-TU-001, while APOE4 status separately determines eligibility for lecanemab in sporadic Alzheimer's disease.
